Literature DB >> 33710027

Tenofovir, pregnancy and renal function changes in pregnant women living with HIV.

Matthew A Thimm1, Ahizechukwu C Eke2.   

Abstract

This retrospective study of 100 pregnant women living with HIV [66 on tenofovir disoproxil fumarate (TDF) compared to 34 women on tenofovir alafenamide (TAF)] found no significant difference in renal function in pregnant women with HIV receiving TDF versus TAF. Our results demonstrate that, in regard to renal toxicity, both TDF and TAF appear to be safe for pregnant women living with HIV, but larger prospective cohort studies in pregnant women living with HIV are encouraged.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33710027      PMCID： PMC8172469          DOI： 10.1097/QAD.0000000000002880

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.632


  8 in total

Review 1.  Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.

Authors:  Xingbao Tao; Yanqiu Lu; Yihong Zhou; Lvlang Zhang; Yaokai Chen
Journal:  Int J Infect Dis       Date:  2020-01-25       Impact factor: 3.623

2.  High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.

Authors:  Anna Bonjoch; Patricia Echeverría; Núria Perez-Alvarez; Jordi Puig; Carla Estany; Bonaventura Clotet; Eugènia Negredo
Journal:  Antiviral Res       Date:  2012-08-06       Impact factor: 5.970

3.  Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Authors:  Mary G Fowler; Min Qin; Susan A Fiscus; Judith S Currier; Patricia M Flynn; Tsungai Chipato; James McIntyre; Devasena Gnanashanmugam; George K Siberry; Anne S Coletti; Taha E Taha; Karin L Klingman; Francis E Martinson; Maxensia Owor; Avy Violari; Dhayendre Moodley; Gerhard B Theron; Ramesh Bhosale; Raziya Bobat; Benjamin H Chi; Renate Strehlau; Pendo Mlay; Amy J Loftis; Renee Browning; Terence Fenton; Lynette Purdue; Michael Basar; David E Shapiro; Lynne M Mofenson
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

4.  Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.

Authors:  C Fafin; P Pugliese; J Durant; V Mondain; V Rahelinirina; F De Salvador; C Ceppi; I Perbost; E Rosenthal; P M Roger; E Cua; P Dellamonica; V Esnault; C Pradier; O Moranne
Journal:  Nephron Clin Pract       Date:  2012-09-29

Review 5.  Tenofovir alafenamide use in pregnant and lactating women living with HIV.

Authors:  Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-17       Impact factor: 4.936

6.  Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Authors:  Andrew Hill; Sophie L Hughes; Dzintars Gotham; Anton L Pozniak
Journal:  J Virus Erad       Date:  2018-04-01

7.  Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.

Authors:  Bernard Surial; Bruno Ledergerber; Alexandra Calmy; Matthias Cavassini; Huldrych F Günthard; Helen Kovari; Marcel Stöckle; Enos Bernasconi; Patrick Schmid; Christoph A Fux; Hansjakob Furrer; Andri Rauch; Gilles Wandeler
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 7.759

8.  Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Authors:  Sophie Jose; Lisa Hamzah; Lucy J Campbell; Teresa Hill; Martin Fisher; Clifford Leen; Richard Gilson; John Walsh; Mark Nelson; Phillip Hay; Margaret Johnson; David Chadwick; Dorothea Nitsch; Rachael Jones; Caroline A Sabin; Frank A Post
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226
  8 in total
  1 in total

1.  Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate.

Authors:  Ahizechukwu C Eke
Journal:  J Pharm Drug Res       Date:  2022-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.